Genome Editing Market Revenue to Cross US$ 14.5 billion by 2035

Published: December 2023


According to a recently published report by Roots Analysis, the potential of genome editing tools as therapeutic modalities for the treatment of chronic diseases is driving the genome editing market growth

Genome Editing Industry Overview

The global genome editing market is anticipated to grow at a CAGR of 12.6% from 2023-2035, reaching USD 14.5 billion by 2035.

The genome editing companies have revolutionized the healthcare domain with their incessant efforts to research and develop precise, safe and efficient genome editing technologies. Apart from their use in the development of cell and gene therapies, these technologies are being used to understand the underlying cause of the disease. Further, the stakeholders have been engaged in exploring the next-generation of CRISPR technologies (base editing and prime editing) that have the ability to circumvent the limitations of conventional techniques, such as off-target side-effects, immunogenicity and toxicity. As a result, licensing of these technologies has become a preferred business model in this domain, allowing drug developers and researchers to leverage a broader range of advanced genome editing technologies.

Browse 105+ figures and 155+ market data tables spread across 350+ pages and detailed Table of Content on “Genome Editing Market (Focus on Technology) by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Gene Delivery Modality, Application Area, Type of End User, Key Geographical Regions and Type of Payment Method Employed: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/genome-editing-market.html

Market Drivers

The ever-growing number of patients for chronic diseases, wherein the underlying cause is the alteration in the genetic make-up, has led to demand for techniques that offer long-term, effective treatment. As a result, gene editing techniques are widely explored to develop gene-edited medicines as a new therapeutic option. These techniques are also being utilized for disease modelling, drug discovery and diagnostics. Moreover, the ongoing innovations in genome editing technologies to overcome several challenges, including lack of multiple editing, efficient insertion of large transgenes and  lack of site specificity, has increased the reliability of the drug developers on the companies developing such technologies. Great progress in developing therapeutics based on engineered genome have paved way for substantial market growth.

Market Restraints

One of the major roadblocks to the adoption of genome editing is the elevated price of the drugs. Genome editing systems are involved in producing precise, targeted genetic manipulation at the target site, due to which, there is an increased cost for therapy. In addition, the time and resources required for the research and production of gene-edited drugs is also high. Moreover, government regulations pose a challenge in the acceptance of gene editing for the development of various therapeutic modalities. These standards are often challenging to meet, which leads to extended development timelines and hence increased costs. In addition, ethical concerns also center around the usage of gene editing in germline gene therapy. Patients often refrain from adopting such techniques due to their additional consequences. As a result, there is an urgent need to refine these concerns posed by gene editing technologies.

Growth Factors

The lucrative opportunity within genome editing market has led to the establishment of several start-ups. These relatively new companies are working on the development of gene editing technologies with emerging techniques, limiting the challenges posed by conventional systems. They are also engaged in the development of a robust pipeline for gene-edited drugs. The recent increase in the number of acquisitions of companies engaged in gene editing domain also demonstrates the interest of established players to incorporate these gene editing technologies in their portfolios. In fact, these established players are expanding their business with the support of small players in creation and development of cell and gene therapies through their proprietary technologies. Moreover, some players are also engaged in the acquisition of production facilities for the production of gene-edited drugs. This trend indicates an opportunity for such companies to provide gene edited drugs with increased capacity and capability.

Genome Editing Market Segments

Based on the type of gene editing technique, the market is segmented into CRISPR-Cas System, TALENs, Meganucleases, ZFNs and Other Techniques

  • The CRISPR-Cas system segment led the genome editing market (technologies), capturing the largest revenue share of close to 80.0% in 2023.
  • In fact, the share of CRISPR-Cas system is unlikely to change during the forecasted period.

Based on the type of therapy, the market is segmented into Cell Therapies, Gene Therapies and Other Therapies

  • The cell therapies segment led the genome editing market (technologies), capturing the largest revenue share of close to 60.0% in 2023.
  • The gene therapies segment is anticipated to show lucrative market growth potential at a CAGR of over 14% during the forecast period.

Based on the gene editing approach, the market is segmented into Gene Knock-Out and Gene Knock-In

  • The gene knock-out segment led the genome editing market (technologies), capturing the largest revenue share of close to 55.0% in 2023.
  • Moreover, the gene knock-out segment is anticipated to show highest market growth potential at a CAGR of over 13% during the forecast period.

Based on the gene delivery method, the market is segmented into Ex-Vivo and In-Vivo

  • The ex-vivo segment led the genome editing market (technologies), capturing the largest revenue share of close to 60.0% in 2023.
  • In fact, the in-vivo segment is anticipated to show highest market growth potential at a CAGR of over 13.5% during the forecast period.

Based on the gene delivery modality, the market is segmented into Viral Vectors and Non-Viral Vectors

  • The viral vectors segment led the genome editing market (technologies), capturing the largest revenue share of 55.0% in 2023.
  • In fact, the non-viral vectors segment is anticipated to show highest market growth potential at a CAGR of over 13.5% during the forecast period.

Based on the application area, the market is segmented into Drug Discovery and Development, and Diagnostics

  • The drug discovery and development segment led the genome editing market (technologies), capturing the largest revenue share of 85.0% in 2023.
  • In fact, the diagnostics segment is anticipated to show highest market growth potential at a CAGR of close to 15% during the forecast period.

Based on the type of end user, the market is segmented into Pharmaceutical and Biotechnology Companies, and Academic and Research Institutes

  • The pharmaceutical and biotechnology companies segment led the genome editing market (technologies), capturing the largest revenue share of close to 80.0% in 2023.
  • Moreover, the academic and research institutes segment is anticipated to show highest market growth potential at a CAGR of over 13.5% during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe and Asia-Pacific

  • North America dominated the genome editing market (technologies) and accounted for the largest revenue share of close to 75.0% in 2023.
  • In Europe, the genome editing market (technologies) is anticipated to demonstrate lucrative growth during the forecast period.

Based on the type of payment model employed, the market is segmented into Upfront Payments and Milestone Payments

  • The upfront payments segment led the genome editing market (technologies), capturing the largest revenue share of close to 55.0% in 2023.
  • In fact, the milestone payments segment is anticipated to show highest market growth potential at a CAGR of over 16% during the forecast period.

Key Companies Profiled

The genome editing market report also includes detailed profiles of key players (listed below) that offer genome editing technologies:

  • Arcturus Therapeutics
  • Avectas
  • Beam Therapeutics
  • Bio-Sourcing
  • Caribou Biosciences
  • Century Therapeutics
  • CRISPR Therapeutics
  • EdiGene
  • Editas Medicine
  • Flash Therapeutics
  • Fortgen
  • G+FLAS Life Sciences
  • Graphite Bio
  • Intellia Therapeutics
  • Ntrans Technologies
  • OXGENE
  • Prime Medicine
  • Revvity (formerly known as Horizon Discovery)
  • TargetGene Biotechnologies
  • Vor Biopharma
  • ZeClinics

You Can Download Free Sample PDF Copy of This Report At: 
https://www.rootsanalysis.com/reports/genome-editing-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry